Generic drug of Dogmatil
Therapeutic Class: Neurology-Psychiatry
active ingredients: Sulpiride
Pill box of 30
- Short - term symptomatic treatment of adult anxiety in case of failure of usual therapies.
- Serious behavioral disorders (agitation, self-injury, stereotyping) in children over 6 years of age, particularly in the context of autistic syndrome s.
Dosage AIGLONYL Ge 50 mg Capsule Pill Box of 30
The minimum effective dosage will always be sought. If the clinical condition of the patient permits, the treatment will be initiated at low dose and then gradually increased in steps.
- In adults:
Short-term symptomatic treatment of adult anxiety in case of failure of usual therapies :
The daily dosage is 50 to 150 mg for a maximum of 4 weeks.
- In children over 6 years old:
Serious behavioral problems (agitation, self-mutilation, stereotypies) especially in the context of autistic syndromes :
The daily dosage is 5 to 10 mg / kg.
In children, the oral solution form is better adapted.
This medicine is CONTRAINDICATED in the following cases:
- hypersensitivity to sulpiride or any of the other constituents of the product,
- pheochromocytoma, known or suspected,
- in association with :
. dopaminergic agonists (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole) outside the patient with Parkinson's disease (see interactions).
The tablet or capsule is contraindicated in children under 6 years of age because it can lead to a wrong route.
Due to the presence of lactose, this drug is contraindicated in cases of congenital galactosemia, glucose-galactose malabsorption syndrome or lactase deficiency.
NOT RECOMMENDED :
This medicine is NOT RECOMMENDED in the following cases:
- Breastfeeding: breastfeeding is not recommended during treatment because of the passage of sulpiride in breast milk,
- in association with :
. the alcohol,
. drugs that may give torsades de pointes: anti-arrhythmics of class la (quinidine, hydroquinidine, disopyramide) and class III (amiodarone, sotalol, dofetilide, ibutilide), certain neuroleptics (thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, amisulpride, tiapride, pimozide, haloperidol, droperidol), and other drugs such as: bepridil, cisapride, diphemanil, erythromycin IV, mizolastine, vincamine IV, halofantrine, pentamidine, sparfloxacin, moxifloxacin ...
. dopaminergic agonists (amantadine, apomorphine, bromocriptine, cabergoline, entacapone, lisuride, pergolide, piribedil, pramipexole, quinagolide, ropinirole) in the Parkinsonian patient (see interactions).
Adverse effects Aiglonyl GE
- Neuropsychic disorders :
. early dyskinesia (spasmodic torticollis, oculogyric seizures, trismus) giving way to anticholinergic antiparkinsonian
. extrapyramidal syndrome:
. akinetic with or without hypertonia, and partially yielding to antiparkinsonian anticholinergics,
. hyperkineto-hypertonic, excito-motor,
. tardive dyskinesias that could be observed as with all neuroleptics during prolonged courses of treatment: antiparkinsonian anticholinergics are without action or can cause an aggravation,
. sedation or drowsiness.
- Endocrine and metabolic disorders :
. transient hyperprolactinemia and reversible upon discontinuation of treatment that may result in amenorrhea, galactorrhea, gynecomastia, impotence or frigidity,
. weight gain.
- Cardiac disorders :
. prolongation of the QT interval.
. very rare cases of torsades de pointes have been reported.
- Neurovegetative disorders :
- Malignant syndrome (see warnings: pallor, hyperthermia, vegetative disorders, impaired consciousness, muscle rigidity, sweating and arterial instability).